Oncology and Therapy最新文献

{"title":"Development of a Conceptual Model of the Patient Experience in Small Cell Lung Cancer: A Qualitative Interview Study.","authors":"Danielle E Altman,&nbsp;Xinke Zhang,&nbsp;An-Chen Fu,&nbsp;Alissa R Rams,&nbsp;Jessica A Baldasaro,&nbsp;Samir Ali Ahmad,&nbsp;Michael Schlichting,&nbsp;Patrick Marquis,&nbsp;Elena Benincasa,&nbsp;Camilo Moulin,&nbsp;Vivek Pawar","doi":"10.1007/s40487-023-00223-w","DOIUrl":"https://doi.org/10.1007/s40487-023-00223-w","url":null,"abstract":"<p><strong>Introduction: </strong>Small cell lung cancer (SCLC) is a subtype of lung cancer, the second most common cancer diagnosis worldwide. Currently, there is little published qualitative research that provides insight into the disease-related symptoms and impacts that are relevant to patients living with SCLC as directly reported by patients themselves.</p><p><strong>Methods: </strong>This qualitative, cross-sectional, noninterventional, descriptive study included concept elicitation interviews with participants diagnosed with SCLC and the development of a conceptual model of clinical treatment benefit.</p><p><strong>Results: </strong>Concept elicitation interview data from 26 participants with SCLC were used to develop a conceptual model of clinical treatment benefit that organized 28 patient-reported concepts into two domains: disease-related symptoms (organ-specific and systemic) and impacts. Organ-specific symptoms included cough, chest pain, and difficulty breathing. Systemic symptoms included pain, fatigue, appetite loss, and dizziness. Impacts included physical functioning, role functioning, reduced movement, impact on sleep, and weight loss.</p><p><strong>Conclusion: </strong>As evidenced by this study, people with SCLC experience considerable and significant symptoms and impacts, including physical and role functioning challenges, that affect their quality of life. This conceptual model will inform the design of a patient-reported outcome (PRO) questionnaire for a future SCLC clinical trial, helping to establish the content validity of the items and questionnaires used in the trial and ensuring that the questionnaires and items selected are appropriately targeted to the population. This conceptual model could also be used to inform future SCLC clinical trials.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"231-244"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/83/40487_2023_Article_223.PMC10260713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9634954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Future of Breast Cancer Research in the Survivorship Field.","authors":"D Soldato, L Arecco, E Agostinetto, M A Franzoi, E Mariamidze, S Begijanashvili, N Brunetti, S Spinaci, C Solinas, I Vaz-Luis, A Di Meglio, M Lambertini","doi":"10.1007/s40487-023-00225-8","DOIUrl":"10.1007/s40487-023-00225-8","url":null,"abstract":"<p><p>Prevalence of survivors of breast cancer has been steadily increasing in the last 20 years. Currently, more than 90% of women diagnosed with early-stage breast cancer are expected to be alive at 5 years from diagnosis thanks to early detection and breakthrough innovations in multimodal treatment strategies. Alongside this advancement in clinical outcomes, survivors of breast cancer might experience several specific challenges and present with unique needs. Survivorship trajectories after diagnosis and treatment of breast cancer can be significantly impacted by long-lasting and severe treatment-related side effects, including physical problems, psychological distress, fertility issues in young women, and impaired social and work reintegration, which add up to patients' individual risk of cancer recurrence and second primary malignancies. Alongside cancer-specific sequelae, survivors still present with general health needs, including management of chronic preexisting or ensuing conditions. Survivorship care should implement high-quality, evidence-based strategies to promptly screen, identify, and address survivors' needs in a comprehensive way and minimize the impact of severe treatment sequelae, preexisting comorbidities, unhealthy lifestyles, and risk of recurrence on quality of life. This narrative review focuses on core areas of survivorship care and discuss the state of the art and future research perspectives in key domains including selected long-term side effects, surveillance for recurrences and second cancers, well-being promotion, and specific survivors' needs.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"199-229"},"PeriodicalIF":3.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/01/40487_2023_Article_225.PMC10260743.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9633488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemistry-Not Oncogenes-May Demystify and Defeat Cancer.","authors":"Jay Kulsh","doi":"10.1007/s40487-023-00221-y","DOIUrl":"https://doi.org/10.1007/s40487-023-00221-y","url":null,"abstract":"<p><p>The presence of mutated genes strongly correlates with the incidence of cancer. Decades of research, however, has not yielded any specific causative gene or set of genes for the vast majority of cancers. The Cancer Genome Atlas program was supposed to provide clarity, but it only gave much more data without any accompanying insight into how the disease begins and progresses. It may be time to notice that epidemiological studies consistently show that the environment, not genes, has the principal role in causing cancer. Since carcinogenic chemicals in our food, drink, air, and water are the primary culprits, we need to look at the biochemistry of cancer, with a focus on enzymes that invariably facilitate transformations in a cell. In particular, attention should be paid to the rate-limiting enzyme in DNA synthesis, ribonucleotide reductase (RnR), whose activity is tightly linked to tumor growth. Besides circumstantial evidence that cancer is induced at this enzyme's vulnerable free-radical-containing active site by various carcinogens, its role in initiating retinoblastoma and human papillomavirus (HPV)-related cervical cancers has been well documented in recent years. Blocking the activity of malignant RnR is a certain way to arrest cancer.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"153-169"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/eb/40487_2023_Article_221.PMC10260729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9991812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance.","authors":"Dana Chase,&nbsp;Jessica Perhanidis,&nbsp;Divya Gupta,&nbsp;Linda Kalilani,&nbsp;Amanda Golembesky,&nbsp;Antonio González-Martín","doi":"10.1007/s40487-023-00227-6","DOIUrl":"https://doi.org/10.1007/s40487-023-00227-6","url":null,"abstract":"<p><strong>Introduction: </strong>We evaluated real-world outcomes in patients with advanced ovarian cancer (AOC) based on their cumulative risk profile and maintenance therapy (MT) status following first-line (1L) treatment.</p><p><strong>Methods: </strong>This retrospective observational study of a nationwide electronic health record-derived de-identified database included adult patients diagnosed with stage III/IV OC from January 1, 2011 to February 28, 2021, who received 1L therapy and had ≥ 12 weeks of follow-up after the index date (end of 1L therapy). Patients were grouped according to whether they received MT or active surveillance (AS) following 1L treatment and by the cumulative number of risk factors (RF) present (stage IV disease; no surgery/treated with neoadjuvant therapy and interval debulking surgery; had postoperative visible residual disease; and had BRCA wild-type disease/unknown BRCA status). Time to next treatment (TTNT) and overall survival (OS) were assessed with a cloning and inverse probability of censoring (IPC)-weighted Kaplan-Meier method.</p><p><strong>Results: </strong>Among 1920 patients, 22.2% received MT and 77.8% received AS. Median IPC-weighted TTNT and OS were 13.3 months (95% CI 11.7-15.8) and 39.1 months (95% CI 32.5-48.6) in the MT cohort, respectively, and 8.6 months (95% CI 8.0-9.5) and 38.4 months (95% CI 36.4-41.0) in the AS cohort, respectively. Almost all patients had ≥ 1 RF (MT 95.3%; AS 96.7%). Median IPC-weighted TTNT was shorter among patients with more RF in both cohorts (MT: 1 RF, 19.3 months, 95% CI 13.5-37.8; 2 RF, 17.2 months, 95% CI 12.8-20.2; 3 RF, 11.0 months, 95% CI 8.2-13.8; 4 RF, 7.0 months, 95% CI 6.2-8.8; AS: 1 RF, 17.7 months, 95% CI 13.5-22.3; 2 RF, 10.2 months, 95% CI 9.1-11.5; 3 RF, 6.5 months, 95% CI 5.8-7.4; 4 RF, 4.1 months, 95% CI 3.5-4.5).</p><p><strong>Conclusion: </strong>Regardless of RF number, MT was associated with longer TTNT in real-world patients with AOC.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"245-261"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/90/40487_2023_Article_227.PMC10260707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9992330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial.","authors":"Emine Eylem Genç,&nbsp;İrem Sena Saraç,&nbsp;Hayrunnisa Arslan,&nbsp;Ahmet Emre Eşkazan","doi":"10.1007/s40487-023-00229-4","DOIUrl":"https://doi.org/10.1007/s40487-023-00229-4","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) can affect individuals of all ages, but is more common in older adults. It has been estimated that AML accounted for 1% of all newly diagnosed cancers in the USA in 2022. The diagnostic process varies depending on the presenting symptoms and the healthcare facility that patients attend at diagnosis. The treatment process is long and prone to complications, requiring experienced medical professionals and appropriate infrastructure. Treatment of the disease did not change greatly over the years until 2017 when targeted therapies were licensed. The treatment of AML is associated with significant direct economic costs. A number of obstacles originating both from individual patients and the healthcare system may be encountered during the diagnosis and treatment of the disease, which may negatively impact the optimal management of the disease process. In this article, we focus primarily on the social, operational, and financial obstacles including the corona virus disease 2019 (COVID-19) pandemic experienced during the diagnosis and treatment of AML.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"145-152"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/03/40487_2023_Article_229.PMC10182356.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9980746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.","authors":"Sundar Jagannath,&nbsp;Nedra Joseph,&nbsp;Concetta Crivera,&nbsp;Akshay Kharat,&nbsp;Carolyn C Jackson,&nbsp;Satish Valluri,&nbsp;Patricia Cost,&nbsp;Hilary Phelps,&nbsp;Rafal Slowik,&nbsp;Timothy Klein,&nbsp;Lee Smolen,&nbsp;Xueting Yu,&nbsp;Adam D Cohen","doi":"10.1007/s40487-023-00228-5","DOIUrl":"https://doi.org/10.1007/s40487-023-00228-5","url":null,"abstract":"<p><strong>Introduction: </strong>Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The objective of this study was to estimate the per-patient US commercial healthcare costs related to cilta-cel (CARVYKTI^®) CAR-T therapy (i.e., costs separate from cilta-cel therapy acquisition) for patients with RRMM.</p><p><strong>Methods: </strong>US prescribing information for cilta-cel, publicly available data, and published literature were used with clinician input to identify the cost components and unit costs associated with administration of cilta-cel. Cost components included apheresis, bridging therapy, conditioning therapy, administration, and postinfusion monitoring for 1 year of follow-up. Adverse event (AE) management costs for all grades of cytokine release syndrome and neurologic toxicities, and additional AEs grade ≥ 3 occurring in > 5% of patients were included in the analysis.</p><p><strong>Results: </strong>The estimated per-patient average costs of cilta-cel CAR-T therapy administered exclusively in an inpatient setting, excluding cilta-cel therapy acquisition costs, totaled US$160,933 over a 12 month period. Costs assuming different proportions of inpatient/outpatient administration (85%/15% and 70%/30%) were US$158,095 and US$155,257, respectively.</p><p><strong>Conclusion: </strong>Cost estimates from this analysis, which disaggregates CAR-T therapy costs, provide a comprehensive view of the cost components of CAR-T therapy that can help healthcare decision-makers make informed choices regarding the use of cilta-cel. Real-world costs may differ with improved AE prevention and mitigation strategies.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"263-275"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/ae/40487_2023_Article_228.PMC10260711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9635468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.","authors":"Shuwen Zheng,&nbsp;Yumei Feng,&nbsp;Chan Li,&nbsp;Jie Zhang,&nbsp;Ke Xie","doi":"10.1007/s40487-023-00226-7","DOIUrl":"https://doi.org/10.1007/s40487-023-00226-7","url":null,"abstract":"<p><p>The optimal approach to locally advanced head and neck squamous cell carcinoma (LAHNSCC) treatment remains controversial. For non-resectable LAHNSCC, the clinical interest of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) or radiotherapy has been questioned. With the approval of immunotherapy and targeted therapy for this disease, treatment options have become more complex. Although new trial data have appeared every year, the results are still inconclusive. In this review, we provide readers with information on new strategies for LAHNSCC induction therapy, which will facilitate evidence-based decision making in LAHNSCC treatment.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"185-198"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/26/40487_2023_Article_226.PMC10260727.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9639346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review.","authors":"Paulo Nunes Filho,&nbsp;Caroline Albuquerque,&nbsp;Mariana Pilon Capella,&nbsp;Marcio Debiasi","doi":"10.1007/s40487-023-00224-9","DOIUrl":"https://doi.org/10.1007/s40487-023-00224-9","url":null,"abstract":"<p><p>Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer's prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 2","pages":"171-183"},"PeriodicalIF":2.7,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/3b/40487_2023_Article_224.PMC10260715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9689921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Patients at the Heart of the Scientific Dialogue: An Industry Perspective.","authors":"Dany Habr,&nbsp;Brittany Wolf Gianares,&nbsp;Kristine W Schuler,&nbsp;Dheepa Chari","doi":"10.1007/s40487-023-00222-x","DOIUrl":"https://doi.org/10.1007/s40487-023-00222-x","url":null,"abstract":"","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 1","pages":"25"},"PeriodicalIF":2.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/43/40487_2023_Article_222.PMC9935758.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10799517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients at the Heart of the Scientific Dialogue: An Industry Perspective.","authors":"Dany Habr, Brittany Wolf Gianares, Kristine W Schuler, Dheepa Chari","doi":"10.1007/s40487-023-00220-z","DOIUrl":"10.1007/s40487-023-00220-z","url":null,"abstract":"","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":"11 1","pages":"15-24"},"PeriodicalIF":2.7,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/c6/40487_2023_Article_220.PMC9881512.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}